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Alcohol problems need more attention in long term opioid substitution treatment  
Opioid substitution treatment (OST) using oral methadone and buprenorphine has 
consistently been shown to substantially reduce illicit heroin use, opioid overdose deaths, and 
HIV infection and to improve the quality of life of persons who are opioid dependent.1 OST 
is usually recommended as a long term maintenance treatment because its benefits are most 
apparent while patients remain in treatment and they rapidly dissipate when patients 
withdraw from treatment.2  
What happens to opioid and other drug use when patients remain in OST for a decade or 
more?  
Marcus Herdener and colleagues answer this question by presenting data on self-reported 
heroin, cocaine, alcohol and benzodiazepine use in a cohort of 8962 Swiss heroin users who 
were enrolled in OST over a period of 17 years between 1998 and 2014. There are very few 
such long term studies of the impact of OST on heroin and other drug use. This is a major gap 
in the literature given that epidemics of heroin use in many developed countries in the 1990s 
created an ageing cohort of opioid dependent people, many of whom have remained in OST 
for several decades.  
Some evidence points to increasing rates of problem alcohol use in long term OST patients. 
An Australian study of mortality in OST patients found increased rates of death from 
cirrhosis, HCV infection and hepatocellular carcinoma as these patients aged.3 Similar results 
have been reported in cohorts in England4 and Sweden.5 These mortality patterns point to 
likely causal roles for high prevalent HBV and HCV infections and heavy alcohol use. 
The authors analysed self-reported data on heroin and other drug use that were routinely 
collected on opioid dependent patients enrolled in OST in the Zurich region of Switzerland. 
The data are all self-report but such data are generally recognised as reasonably reliable if 
participants do not have any incentives to under-report.6 This seems to have been the case in 
Zurich where continued heroin and cocaine use did not lead to discharge from the program.  
Their analyses showed a sharp decline in heroin use on first admission to treatment and a 
steady decline in frequent heroin (from 14·4% to 6%) and cocaine use (from 8·5% to 4·9%) 
over the 17 year study period. They also found, as expected, that declines in heroin and 
cocaine use were associated with improved social integration and there was a decline in 
social integration if the frequency of heroin or cocaine use increased.  
By contrast, the proportion of patients who engaged in frequent alcohol use steadily increased 
over the study period by the end of which nearly one in four patients (22·5%) were frequent 
users of alcohol. This probably reflects the greater availability of a cheaper, legal drug like 
alcohol than heroin or cocaine as opioid dependent persons age. 
The authors very reasonably propose that OST programs should make more of an effort to 
address problem alcohol use by their patients. This is especially relevant given the increased 
vulnerability of OST patients to liver disease because of their high rates of chronic hepatitis B 
and C infection. Heavy alcohol use also increases the risks of fatal opioid overdose if it is 
combined with injecting opioid use.7  
The fact that many of these patients remain in OST represents an underused opportunity to 
identify and treat their problem alcohol use. These patients regularly attend the services to 
receive doses of replacement opioids and so can be readily assessed and counselled. Arguably 
all patients in OST should be routinely asked about their drinking and those who are drinking 
heavily advised to cut down the frequency and quantity of their alcohol use.8 Those who 
struggle to enact this advice on their own should be offered referral for assessment and 
interventions such as CBT and pharmacotherapy. As the authors point out, their opioid 
dependence precludes the use of the opioid antagonists like naltrexone and namalfene but 
they can still be offered acamprosate and disulfiram, if this is not contraindicated by 
compromised liver function or disease.8  
The impact of long term OST on benzodiazepine use was less clear cut. Regular use remained 
at low rates but there was a small increase over the study period (10% to 11·1%). This may 
reflect continued maintenance prescribing of benzodiazepines by OST clinics or general 
practitioners to avoid patients resorting to the black market for these drugs. This practice also 
should be evaluated given the poorer social integration of regular benzodiazepine users in this 
and other cohorts9 and the increased risks of overdose when opioids are used in combination 
with benzodiazepines.7 
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